相关实验视频
Updated: Jul 12, 2025

10:36
Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
19.5K
益生菌治疗对多重神经递质障碍儿童神经心理症状的影响:一项研究
Loredana Matiș1, Bogdana Ariana Alexandru1, Radu Fodor1
1Faculty of Medicine and Pharmacy, Medicine Department, University of Oradea, 410068 Oradea, Romania.
Biomedicines
|October 28, 2023
概括
精神生物药物,有益的肠道细菌,在改善儿童的行为和注意力集中方面表现有前途. 这项研究发现,它们可以降低患有胃肠道和精神情绪障碍的儿童的过度活跃和侵略性.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 精神病学是一个精神病学.
背景情况:
- 益生菌或精神生菌与认知功能,记忆,学习和行为有关.
- 它们的积极影响超越了消化道,影响了心理健康.
研究的目的:
- 为了检查经过精神生物治疗的患有胃肠道疾病的儿童的精神情绪影响和认知功能.
- 评估精神生物药对神经递质水平和神经精神病症状的影响.
主要方法:
- 135名5-18岁的患有胃肠道问题的儿童被分为控制,精神焦虑和精神障碍组.
- 对神经递质水平 (血清素,GABA,谷氨酸,皮质醇,DHEA) 进行监测.
- 评估了神经心理症状 (头痛,疲劳,情绪波动,多动,攻击性,睡眠障碍,注意力集中).
主要成果:
- 精神药物显著降低了儿童的过度活跃和侵略性.
- 在度水平上观察到改善.
- 这项研究提供了对儿科神经精神疾病中肠-大脑轴的见解.
结论:
- 精神生物药物对减少多动性和侵略性等有问题的行为产生了重大影响.
- 这些发现表明,精神生物药物是平衡儿童神经心理行为的潜在治疗途径.
- 需要进一步进行广泛的研究,以充分理解肠道健康和儿童心理学之间的复杂相互作用.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
272
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
272
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
696
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
696
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Drug Therapy
47
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
47
Excitatory and Inhibitory Effects of Neurotransmitters
10.0K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
10.0K

